Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-12-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Limitation of expiratory flows is considered as the main determiner of dynamic distension and dyspnoea in chronic obstructive pulmonary disease (COPD). The analysis of proximal and distal resistances should allow to better appreciate the functional impact.

This study should also allow to specify the best parameters in respiratory functional explorations useful for the follow-up in COPD and to specify the relevance of functional indications other than the forced expiration volume at 1 second (FEV1) or the functional residual capacity (FRC) to estimate in a more relevant way the clinical improve with the increase of the therapeutic load (increase of posology, association of two bronchodilatators, addition of an anti-inflammatory drug, thus etc…) at already handled patients suffering from a persistent dyspnoea insufficiently relieved.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intermittent Intrapulmonary Deflation and Dyspnea Following Exercise in People With Chronic Obstructive Pulmonary Disease

NCT06956742

Chronic Obstructive Pulmonary Disease (COPD)

RECRUITING NA

Evaluation by Electrical Impedancemetry of the Variation in Lung Volumes Under Non-invasive Ventilation (NIV) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05953298

COPD

COMPLETED NA

Predictive Factors of Obesity-hypoventilation Syndrome (OHS) Among Obese Subjects- ETUDE COHYPOB -

NCT02021448

Obesity-hypoventilation Syndrome Nocturnal Alveolar Hypoventilation

TERMINATED NA

Study of the Cytokine Response During Exercise Dyspnea in Patients With Chronic Obstructive Pulmonary Disease (COPD). Effect of Body Composition

NCT06229509

Chronic Obstructive Pulmonary Disease Severe Dyspnea

NOT_YET_RECRUITING NA

Search of a Paradoxical Fall in Maximum Expiratory Flow After Bronchodilation in Healthy Subjects

NCT03062904

Paradoxical Fall in Maximum Expiratory Flows

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD

Group Type EXPERIMENTAL

COPD

Intervention Type OTHER

Plethysmography

COPD

Intervention Type OTHER

Forced oscillations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COPD

Plethysmography

Intervention Type OTHER

COPD

Forced oscillations

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD with dyspnoea with Medical Research Council scale (MRC) \>1,
* No exacerbation for 6 weeks
* No bronchodilatator short action(share) (ß 2 agonist or ipratropium) within 6 hours before the respiratory evaluation and the test of reversibility.
* Patient under current treatment (ß2 long-acting agonist (LABA) or anticholinergic long-acting (LLAMA(LAMA)) or LABA-corticoid association inhaled (CSI), or triples LABA-CSI-LAMA association) stable for at least 4 weeks, and taken for at least the 1 hour the day of the visit
* Having given a written consent

Exclusion Criteria

* Patient Under 18
* Other respiratory illness
* Clinically significant left cardiac failure
* Obesity with BMI \> 35 kg / m2)
* Unable to perform respiratory evaluations
* Contraindication to the salbutamol or to the ipratropium bromide or to one of its components
* Pregnant or breast-feeding woman
* Unable to agree
* No social security scheme

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No